Health Act 1947 (Section 31A - Temporary Restrictions) (Covid-19) (Amendment) (No. 2) Regulations 2021

• Jurisdiction: Ireland
• Citation: IR SI 193/2021
• Year: 2021

Notice of the making of this Statutory Instrument was published in

“Iris Oifigiúil” of 27th April, 2021.

I, STEPHEN DONNELLY, Minister for Health, in exercise of the powers conferred on me by sections 5 and 31A (inserted by section 10 of the Health (Preservation and Protection and other Emergency Measures in the Public Interest) Act 2020 (No. 1 of 2020)) of the Health Act 1947 (No. 28 of 1947) and –

(a) having regard to the immediate, exceptional and manifest risk posed to human life and public health by the spread of Covid-19 and to the matters specified in subsection (2) of section 31A,

and

(b) having consulted with the Minister for Foreign Affairs, the Minister for Housing, Local Government and Heritage, the Minister for Transport, the Minister for Enterprise, Trade and Employment, the Minister for Finance, the Minister for Justice and the Minister for Tourism, Culture, Arts, Gaeltacht, Sport and Media,

hereby make the following regulations:

1. (1) These Regulations may be cited as the Health Act 1947 (Section 31A - Temporary Restrictions) (Covid-19) (Amendment) (No. 2) Regulations 2021.

(2) These Regulations shall come into operation on the 26th day of April 2021.

2. In these Regulations, “Principal Regulations” means the Health Act 1947 (Section 31A - Temporary Restrictions) (Covid-19) Regulations 2021 (S.I. No. 168 of 2021).

3. Regulation 3 of the Principal Regulations is amended –

(a) by the insertion of the following definitions:

“ ‘dance rehearsal event’ means an event held or to be held in a location other than in a dwelling wholly or partly for the purposes of –

(a) learning, rehearsing, practising or choreographing a dance or dance routines, or

(b) training or preparing for a dance competition or examination;

‘relevant recreational premises’ means a premises that is –

(a) a botanical garden,

(b) a nature reserve,

(c) an outdoor heritage site,

(d) an outdoor tourism site,

(e) a zoo that is –

(i) licenced in accordance with the European Communities (Licensing and Inspection of Zoos) Regulations 2003 ( S.I. No. 440 of 2003 ), or

(ii) exempted from the requirements of the European Communities (Licensing and Inspection of Zoos) Regulations 2003 in accordance with Regulation 11 of those Regulations,

(f) a wildlife park, or other outdoor animal collection, that is not a zoo,

(g) an outdoor premises that maintains farm animals in order to attract visitors for leisure purposes, or

(h) used for outdoor sporting, outdoor recreational or outdoor exercise purposes,

but does not include –

(i) a funfair,

(ii) a theme park or amusement park,

(iii) a circus,

(iv) a campsite,

(v) a caravan park, or

(vi) an aquarium;”,

(b) in the definition of “relevant event” –

(i) in paragraph (c), by the substitution of “sporting event,” for “sporting event, or”,

(ii) in paragraph (d), by the substitution of “training event, or” for “training event;”, and

(iii) by the insertion of the following paragraph after paragraph (d):

“(e) a dance rehearsal event;”, and

(c) by the substitution of the following definition for the definition of “vaccinated person”:

“ ‘vaccinated person’ means –

(a) in relation to a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘COVID-19 Vaccine Moderna CX-024414’ has been administered –

(i) as part of the vaccination programme against Covid-19 implemented by the Health Service Executive on behalf of the State, or

(ii) as part of a vaccination programme (howsoever described) against Covid-19 implemented on behalf of another state, country, territory, region or other place outside the State,

such person not less than 14 days after a second dose of that medicinal product has been administered to that person,

(b) in relation to a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘Vaxzevria (previously COVID-19 Vaccine AstraZeneca) ChAdOx1-SARS-COV-2’ has been administered –

(i) as part of the vaccination programme against Covid-19 implemented by the Health Service Executive on behalf of the State, or

(ii) as part of a vaccination programme (howsoever described) against Covid-19 implemented on behalf of another state, country, territory, region or other place outside the State,

such person not less than 15 days after a second dose of that medicinal product has been administered to that person,

(c) in relation to a person to whom the medicinal product authorised for active immunisation to prevent Covid-19 known as ‘Comirnaty BNT162b2’ has been administered –

(i) as part of the vaccination programme against Covid-19 implemented by the Health Service Executive on behalf of the State, or

(ii) as part of a vaccination programme (howsoever described) against Covid-19 implemented on behalf of another state, country, territory, region or other place outside the State,

such person not less than 7 days after a second dose of that medicinal product has been administered to that person, or

(d) in relation to a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘COVID-19 Vaccine Janssen (Ad26.COV2-S...